Yuhong Li

21PUBLICATIONS
46CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsDisease surveillance
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Sep 11, 2026
Circulating tumour DNA to guide rechallenge with cetuximab plus irinotecan in RAS/BRAF wild-type metastatic colorectal cancer: A nonrandomised clinical trial.

|Jan 22, 2026
A clinical-molecular nomogram for predicting early recurrence following resection of initially unresectable colorectal liver metastases.

Yu-Ting Lu, Xiao-Xia Huang, Wen-Chuan Chen

|Dec 12, 2025
Prognostic Significance of SOX9 and Its Combination With RAS and TP53 Mutations Following Colorectal Cancer Liver Metastasectomy.

Jian-Li Duan, Lei Wen, Yan-Yu Cai

|May 10, 2024
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.

De-Shen Wang, Chao Ren, Shan-Shan Li

|Mar 01, 2024
Methylated ctDNA predicts early recurrence risk in patients undergoing resection of initially unresectable colorectal cancer liver metastases.

Zhi-Gang Chen, Xiao-Meng Ji, Yu-Xia Xu

|Jan 11, 2024
Clinical and molecular characteristics of RNF43 mutations as promising prognostic biomarkers in colorectal cancer.

Zi-Yao Huang, Lei Wen, Liu-Fang Ye

Pageof 4

Frequent Collaborators

8 joint publications

Deshen Wang

6 joint publications

Rui-Hua Xu

3 joint publications

Feng-Hua Wang

3 joint publications

Hui-Yan Luo